Suppr超能文献

糖尿病与透明细胞肾细胞癌患者的死亡率升高独立相关。

Diabetes mellitus is independently associated with an increased risk of mortality in patients with clear cell renal cell carcinoma.

机构信息

Department of Urology, Mayo Clinic, Rochester, Minnesota.

Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota.

出版信息

J Urol. 2014 Dec;192(6):1620-7. doi: 10.1016/j.juro.2014.06.014. Epub 2014 Jun 12.

Abstract

PURPOSE

Conflicting data exist on the interaction of diabetes mellitus with outcomes in patients with renal cell carcinoma. We evaluated the association of diabetes mellitus with survival in patients with clear cell renal cell carcinoma treated with nephrectomy.

MATERIALS AND METHODS

We reviewed the records of 1,964 patients treated surgically for sporadic, unilateral, M0 clear cell renal cell carcinoma between 1990 and 2008. One pathologist re-reviewed all specimens to confirm clear cell renal cell carcinoma. We matched 257 patients with diabetes 1:2 to referent patients without diabetes according to clinicopathological and surgical features. Cancer specific and overall survival was estimated using the Kaplan-Meier method. Cox models were used to evaluate associations with outcomes.

RESULTS

A total of 257 patients (13%) had diabetes mellitus. They were significantly older and more likely to be obese, and had higher Charlson scores, renal impairment and smoking rates, and worse performance status at surgery (p <0.001). Pathological features were similar between the groups. Median postoperative followup was 8.7 years. Five-year cancer specific survival was similar in patients with and without diabetes (82% vs 86%, p = 0.1) while 5-year overall survival was significantly worse in those with diabetes (65% vs 74%, p <0.001). On multivariable analysis diabetes mellitus independently predicted cancer specific mortality (HR 1.55, 95% CI 1.08-2.21, p = 0.02) and all-cause mortality (HR 1.32, 95% CI 1.06-1.64, p = 0.01).

CONCLUSIONS

Our results suggest that diabetes mellitus is independently associated with decreased cancer specific and overall survival in patients with surgically treated clear cell renal cell carcinoma.

摘要

目的

关于糖尿病与肾细胞癌患者结局的相互作用,目前存在相互矛盾的数据。我们评估了糖尿病与接受肾切除术治疗的透明细胞肾细胞癌患者生存的相关性。

材料与方法

我们回顾了 1990 年至 2008 年间 1964 例接受手术治疗的散发性、单侧、M0 透明细胞肾细胞癌患者的记录。一名病理学家重新审查了所有标本,以确认透明细胞肾细胞癌。根据临床病理和手术特征,我们将 257 例糖尿病患者与 257 例对照患者 1:2 匹配。使用 Kaplan-Meier 方法估计癌症特异性和总体生存率。使用 Cox 模型评估与结果的相关性。

结果

共有 257 例(13%)患者患有糖尿病。他们年龄更大,更可能肥胖,Charlson 评分更高,肾功能不全和吸烟率更高,手术时的表现状态更差(p<0.001)。两组的病理特征相似。术后中位随访时间为 8.7 年。糖尿病患者和无糖尿病患者的 5 年癌症特异性生存率相似(82% vs 86%,p=0.1),但糖尿病患者的 5 年总生存率明显较差(65% vs 74%,p<0.001)。多变量分析显示,糖尿病独立预测癌症特异性死亡率(HR 1.55,95%CI 1.08-2.21,p=0.02)和全因死亡率(HR 1.32,95%CI 1.06-1.64,p=0.01)。

结论

我们的结果表明,糖尿病与接受手术治疗的透明细胞肾细胞癌患者的癌症特异性和总体生存率降低独立相关。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验